Molbio Diagnostics Q2 FY27 Consolidated Results And Key Board Outcomes
Molbio Diagnostics Ltd · Outcome · 05 Nov 2026, 11:03 pm
Molbio Diagnostics Q2 FY27 Consolidated Results And Key Board Outcomes Molbio Diagnostics reported consolidated revenue from operations of ₹2,590.20 million for the quarter ended 30th Sep'26, down from ₹4,083.76 million in the preceding quarter. Net profit stood at ₹77.01 million compared to ₹527.44 million in Q1 FY27, with diluted EPS at ₹1.33. For H1 FY27, consolidated revenue reached ₹6,673.96 million with PAT of ₹604.45 million. Additionally, the board approved the IPO Monitoring Agency Report, noted the resignation of President & CMO Dr. Kuldeep Singh Sachdeva effective 21st Jan'27, and appointed secretarial auditors.
Original exchange filing (PDF)
More announcements from Molbio Diagnostics Ltd
- Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026 · 11 Nov 2026
- Monitoring Agency Report on the utilization of proceeds raised through issuance of equity shares by way of Public Issue of the Company · 07 Nov 2026
- Audio Recording of Earnings call held on November 05,2026 for the quarter and half year ended September 30,2026. · 06 Nov 2026
- Outcome of Board meeting held on Thursday, November 05, 2026 · 06 Nov 2026
- Investor presentation · 05 Nov 2026
- Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Intimation of Earnings Conference Call on November 05, 2026, at 05:30 P.M. IST to discuss the financial performance of the Company for the quarter and half year ended September 30, 2026. · 05 Nov 2026
- To consider and approve the Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 05 Nov 2026
